For information, this article is an article sponsored by our partner Alcediag and in connection with innovation in the field of mental health.
The diagnosis of bipolarity is often complex, it takes about 8 to 10 years on average. Indeed, it is not always easy to differentiate this disorder from a “classical” depression, especially when the person is in a depressive phase. But today, new solutions exist. And that's where Alcediag, with its innovative blood test EDIT-B, brings a perspective that could change the way bipolarity is diagnosed. This test makes it possible to be more accurate, even during depressive phases, based on biological data. Today, I am going to explain to you why this test is a major advance and how it can facilitate the determination and acceptance of the diagnosis.
Bipolarity is a mood disorder characterized by fluctuations between phases of intense hypomania (or mania) and phases of deep depression. However, the symptoms of bipolarity vary from individual to individual, making diagnosis difficult. The World Health Organization estimates that 2% of the population is affected by bipolarity, but that a large proportion of bipolar people remain underdiagnosed or misdiagnosed. This is mainly due to the variability of symptoms, which can occur differently over the years.
The symptoms of bipolarity overlap with those of other disorders, including unipolar depression, making diagnosis complex. A misdiagnosis, often of depression, leads to inadequate treatments, such as prescribing antidepressants without mood stabilizers, which can worsen symptoms and cause manic episodes. In addition, a prolonged diagnostic error has a major impact on the patient's personal, professional and social life.
Receiving a Diagnosis Bipolarity is an essential step for those affected. This diagnosis makes it possible to better understand mood fluctuations, to obtain appropriate treatment, and above all to give meaning to years of suffering that are often misunderstood. But, as was said before, many people with bipolar disorder are misdiagnosed.
This is where traditional diagnostic methods reach their limits. They are mainly based on subjective questionnaires and evaluations, which can be influenced by the emotional state of the moment. Alcediag has therefore developed a complementary method based on blood biomarkers : EDIT-B, to improve the percentage of success and to offer a more objective and reliable diagnosis.
EDIT-B is based on a simple principle: detecting bipolarity through a blood test. This test identifies specific blood biomarkers linked to bipolarity, which makes it possible to differentiate this condition from a depression purely unipolar.
Here's how it goes:
It's only available in the European Union at the moment.
This innovative approach puts forward an objective method, based on tangible biological data rather than on psychological observations that can sometimes lead to confusion. In addition, EDIT-B is particularly useful when symptoms are difficult to assess or when bipolarity is mainly manifested by depressive episodes.
The Diagnosis of bipolarity is often a step in its own right for those affected. But with a clear and objective diagnosis like that provided by the test EDIT-B, this acceptance process can be facilitated. Having a biological component can reassure patients and help them accept their condition more easily.
The solid scientific data behind the test helps to remove some of the doubt that can sometimes accompany the diagnosis of bipolarity. This allows patients to focus on their supported, knowing that their diagnosis is based on solid foundations and not only on subjective evaluations.
The biological dimension of EDIT-B reinforces the confidence of patients and health professionals. By relying on tangible evidence, this test makes it possible to overcome the doubts often associated with a diagnosis based solely on behavioral observations. Many patients reported that the objectivity of this test helped them to better accept their diagnosis and to feel more involved in their care journey. For this reason, we chose Alcediag as a partner, because we are convinced that acceptance is the most important step for stabilization.
The objective results provided by EDIT-B facilitate communication between the patient and the doctor. This approach based on objective elements reinforces the relationship of trust, allowing patients to better understand the importance of appropriate treatment and to feel supported in their therapeutic approach. This optimizes collaboration between doctor and patient, which improves treatment results and reduces the risk of relapses.
One of the biggest challenges for health professionals is Differentiating bipolarity from depression unipolar, especially when patients are in a depressive phase. Bipolarity is characterized by episodes of manic or hypomanic phase and episodes of depression, but many bipolar people are often misdiagnosed as “only depressed.”
That's where EDIT-B becomes essential. By identifying specific blood biomarkers, this test makes it possible to remove doubts and to make a clear diagnosis, even when the person is in a depressive phase. This means that patients get the right treatment more quickly, tailored to their specific condition, which can make a big difference in managing their mental health condition.
To find out more about the specifics of this test, you can consult the technical details here: EDIT-B test.
The test EDIT-B by Alcediag is much more than just a diagnostic method. It is a real revolution in the way in which bipolarity is diagnosed, allowing patients to receive a faster, more accurate, and above all, better accepted diagnosis. Based on biological data, this test makes it possible to differentiate bipolarity from depression at the first consultations, thus guaranteeing a supported adapted from the start.
EDIT-B could well change the situation in the field of sanity, by offering patients and health professionals a reliable and accessible diagnostic tool. If you want to know more about this innovative test, go to the site of Alcediag to find out how it can transform the diagnosis of bipolarity.
Thanks to advances like EDIT-B, the future of diagnosing bipolarity seems more accurate and more promising. Alcediag offers an innovative method, based on biological evidence, that helps to make more accurate diagnoses and better understand this complex condition. If you have questions about your own diagnosis or that of a loved one, don't hesitate to explore this new method that could change your life.
